CN109091478A - 尿囊素在制备抗高尿酸血症和抗痛风药物中的应用 - Google Patents
尿囊素在制备抗高尿酸血症和抗痛风药物中的应用 Download PDFInfo
- Publication number
- CN109091478A CN109091478A CN201710467560.1A CN201710467560A CN109091478A CN 109091478 A CN109091478 A CN 109091478A CN 201710467560 A CN201710467560 A CN 201710467560A CN 109091478 A CN109091478 A CN 109091478A
- Authority
- CN
- China
- Prior art keywords
- hyperuricemia
- gout
- allantoin
- uric acid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 229960002708 antigout preparations Drugs 0.000 title claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 13
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 title abstract description 78
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 title abstract description 39
- 229960000458 allantoin Drugs 0.000 title abstract description 39
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 33
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229940116269 uric acid Drugs 0.000 claims abstract description 33
- 201000005569 Gout Diseases 0.000 claims abstract description 18
- 230000036541 health Effects 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 12
- 230000009467 reduction Effects 0.000 claims abstract description 7
- 210000004369 blood Anatomy 0.000 claims abstract description 6
- 239000008280 blood Substances 0.000 claims abstract description 6
- 238000005259 measurement Methods 0.000 claims abstract description 5
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000013459 approach Methods 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 13
- 108020004999 messenger RNA Proteins 0.000 abstract description 11
- 102100036930 Solute carrier family 22 member 6 Human genes 0.000 abstract description 7
- 206010067484 Adverse reaction Diseases 0.000 abstract description 4
- 230000006838 adverse reaction Effects 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 abstract description 3
- 101000713272 Homo sapiens Solute carrier family 22 member 4 Proteins 0.000 abstract 1
- 108091006739 SLC22A6 Proteins 0.000 abstract 1
- 102100036928 Solute carrier family 22 member 4 Human genes 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 19
- 239000000243 solution Substances 0.000 description 14
- 239000003826 tablet Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- -1 imidazoles heterocyclic compounds Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 101710102683 Solute carrier family 22 member 6 Proteins 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 210000001643 allantois Anatomy 0.000 description 5
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DIBAKBGYJUCGDL-UHFFFAOYSA-N 2,6-diamino-n-[1-[(2-amino-2-oxoethyl)amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]hexanamide Chemical compound NCCCCC(N)C(=O)NC(C(=O)NCC(N)=O)CC1=CN=CN1 DIBAKBGYJUCGDL-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 108010026970 bursopoietin Proteins 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229950000193 oteracil Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 101000713281 Mus musculus Solute carrier family 22 member 6 Proteins 0.000 description 2
- 108091006764 Organic cation transporters Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- IAPCTXZQXAVYNG-UHFFFAOYSA-M Potassium 2,6-dihydroxytriazinecarboxylate Chemical compound [K+].[O-]C(=O)C1=NC(=O)NC(=O)N1 IAPCTXZQXAVYNG-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012445 acidic reagent Substances 0.000 description 2
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000037427 ion transport Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 101100094850 Mus musculus Slc22a4 gene Proteins 0.000 description 1
- 101100094860 Mus musculus Slc22a6 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- JKQOBWVOAYFWKG-UHFFFAOYSA-N molybdenum trioxide Chemical compound O=[Mo](=O)=O JKQOBWVOAYFWKG-UHFFFAOYSA-N 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000001751 uricolytic effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了尿囊素在抗高尿酸血症和/或抗痛风药物和/或保健品制备中的应用,高尿酸血症包括原发性与继发性高尿酸血症以及各种因素引起的血液中尿酸浓度高于(男)420μmol/L,(女)357μmol/L(磷钨酸还原法测定),或尿酸酶‑过氧化物酶偶联法测定高于420μmol/L的成人,痛风包括原发性痛风与继发性痛风。本发明发现,尿囊素能显著降低小鼠血清尿酸水平,显著增加OAT1、OCTN1的mRNA表达。尿囊素可用于制备治疗抗高尿酸血症和/或抗痛风药物和/或保健品,减少不良反应,为疾病的治疗和预防提供一种安全、有效、经济的解决办法。
Description
技术领域
本发明涉及尿囊素在制备药物中的新应用,主要涉及尿囊素在制备抗痛风药物中的应用,特别涉及尿囊素在制备抗高尿酸血症药物和/或保健品中的应用,属于医药技术领域。
背景技术
痛风是单钠尿酸盐沉积形成晶体所导致的关节病,与嘌呤代谢紊乱及(或)尿酸***减少所引发的高尿酸血症直接相关。
最新观点认为痛风的临床病程包括:(1)高尿酸血症,无尿酸结晶,无痛风症状;(2)观察到尿酸结晶或结石存在,无痛风症状;(3)体内沉积尿酸结晶,痛风急性发作或有发作史;(4)严重痛风,有痛风石形成,造成慢性痛风性关节炎与痛风性肾病。
高尿酸血症是指成人血浆尿酸浓度≥7mg/dL(男性)或5.6mg/dL(女性)的状态,是由于人体内尿酸生成增加和(或)***减少所导致。
高尿酸血症的治疗可分为药物治疗和非药物治疗。临床研究报告显示,非药物治疗仅能降低约10~18%血浆尿酸水平,因此对高尿酸血症的药物治疗是必要的。
高尿酸血症的治疗药物可分为降尿酸药物与控制急性炎症发作的抗炎药物。降尿酸药按作用机制可分减少尿酸生成的黄嘌呤氧化酶抑制剂、增加尿酸***的促尿酸***药和分解尿酸的尿酸酶三类。但现有各药物均有不同程度的不良反应,如别嘌呤醇的超敏反应综合征,所以不够理想。
尿囊素(Allantoin)属咪唑类杂环化合物。化学名:N-(2,5-二氧代咪唑烷-4-基)脲,分子式为C4H6O3N4。能溶于水。纯品为无毒无味,无刺激性、无过敏性的白色晶体,在非水溶液、干燥空气、pH为4~9的溶液中均能保持稳定,在强碱溶液中呈两性。尿囊素广泛存在于哺乳动物的尿和动、植物的胚胎内,因其最早发现于牛的尿囊分泌液中,故名尿囊素。尿囊素具有促进细胞增长,软化角质层蛋白的生理功能;与干燥氢氧化铝凝胶混合,用于消化道溃疡的治疗;也可用来治疗皮肤干燥症和鳞屑性皮肤疾患;此外还可用于糖尿病、肝硬化、癌症、骨髓炎等的治疗。其化学结构如下:
近年来,对尿囊素的降压等药理作用有所报道,但对其在制备抗高尿酸血症和/或抗痛风药物和/或保健品中的作用尚未见报道。
发明内容
本发明解决的技术问题在于提供尿囊素在制备抗高尿酸血症和/或抗痛风药物和/或保健品中的应用,从而为降尿酸治疗提供一种不良反应轻微的解决办法。
为此,本发明提供了如下技术方案:
发明提供了尿囊素在制备抗高尿酸血症和/或抗痛风药物或/和保健品中的应用。
进一步,所述的高尿酸血症包括但不限于原发性与继发性以及各种因素引起的血液中尿酸浓度高于(男)420μmol/L,(女)357μmol/L(磷钨酸还原法测定),或尿酸酶-过氧化物酶偶联法测定高于420μmol/L的成人。
进一步,所述的痛风包括但不限于原发性痛风与继发性痛风。
进一步,所述尿囊素可与药学上可接受的辅料按常规制剂方法制成各种剂型的抗高尿酸血症和/或抗痛风药物。
进一步,所述尿囊素可与保健品包括保健食品和功能食品可接受的辅料按常规制剂方法制成各种抗高尿酸血症和/或抗痛风的保健品。
本发明因此还涉及以本发明化合物作为活性成分的药物组合物。该药物组合物可根据本领域公知的方法制备。可通过发明所述尿囊素与一种或多种药学上可接受的固体或液体赋形剂和/或辅料组合,制成与人或动物使用的任何剂型。本发明化合物在其药物组合物中的含量通常为0.1-99%。
进一步,本发明还涉及以本发明化合物作为活性成分的保健品组合物。该组合物可根据本领域公知的方法制备。可通过发明所述尿囊素与一种或多种保健品和食品上可接受的固体或液体赋形剂和/或辅料组合,制成与人或动物使用的任何剂型。本发明化合物在其药物组合物中的含量通常为0.1-99%。
本发明化合物或含有它的药物组合物可以单位剂量形式给药,给药途径可以为胃肠道或非肠道,如口服、静脉注射、肌肉注射、皮下注射、鼻腔、口腔粘膜、眼、肺和呼吸道、皮肤、***、直肠等。
所述的药物组合剂型包括口服制剂,注射给药剂型,皮肤黏膜途径给药剂型。
根据权利要求7的应用,其特征在于:所属的口服制剂包括片剂、缓释剂、胶囊剂、控释剂、滴丸剂、液体制剂,所述的注射给药剂型包括肌肉注射、静脉注射、静脉滴注。
给药剂型可以是液体剂型、固体剂型或半固体剂型。液体剂型可以是溶液剂(包括真溶液和胶体溶液)、乳剂(包括o/w型、w/o型和复乳)、混悬剂、注射剂(包括水针剂、粉针剂和输液)、滴眼剂、滴鼻剂、洗剂和搽剂等;固体剂型可以是片剂(包括普通片、肠溶片、含片、分散片、咀嚼片、泡腾片、口腔崩解片)、胶囊剂(包括硬胶囊、软胶囊、肠溶胶囊)、颗粒剂、散剂、微丸、滴丸、栓剂、膜剂、贴片、气(粉)雾剂、喷雾剂等;半固体剂型可以是软膏剂、凝胶剂、糊剂等。
本发明化合物可以制成普通制剂、也制成是缓释制剂、控释制剂、靶向制剂及各种微粒给药***。
为了将本发明化合物制成片剂,可以广泛使用本领域公知的各种赋形剂,包括稀释剂、黏合剂、润湿剂、崩解剂、润滑剂、助流剂。稀释剂可以是淀粉、糊精、蔗糖、葡萄糖、乳糖、甘露醇、山梨醇、木糖醇、微晶纤维素、硫酸钙、磷酸氢钙、碳酸钙等;湿润剂可以是水、乙醇、异丙醇等;粘合剂可以是淀粉浆、糊精、糖浆、蜂蜜、葡萄糖溶液、微晶纤维素、***胶浆、明胶浆、羧甲基纤维素钠、甲基纤维素、羧丙基甲基纤维素、乙基纤维素、丙烯酸树脂、卡波姆、聚乙烯吡咯烷酮、聚乙二醇等;崩解剂可以是干淀粉、微晶纤维素、低取代羟丙基纤维素、交联聚乙烯吡咯烷酮、交联羧甲基纤维素钠、羧甲基淀粉钠、碳酸氢钠与枸橼酸、聚氧乙烯山梨糖醇脂肪酸酯、十二烷基磺酸钠等;润滑剂和助流剂可以是滑石粉、二氧化硅、硬脂酸盐、酒石酸、液体石蜡、聚乙二醇等。
还可以将片剂进一步制成包衣片,例如糖包衣片、薄膜包衣片、肠溶包衣片,或双层片和多层片。
为了将给药单元制成胶囊剂,可以将有效成分本发明化合物与稀释剂、助流剂混合,将混合物直接置于硬胶囊或软胶囊中。也可将有效成分本发明化合物先与稀释剂、黏合剂、崩解剂制成颗粒或微丸,再置于硬胶囊或软胶囊中。用于制备本发明化合物片剂的各稀释剂、黏合剂、润湿剂、崩解剂、助流剂品种也可用于制备本发明化合物的胶囊剂。
为将本发明化合物制成注射剂,可以用水、乙醇、异丙醇、丙二醇或它们的混合物作溶剂并加入适量本领域常用的增溶剂、助溶剂、pH调剂剂、渗透压调节剂。增溶剂或助溶剂可以是泊洛沙姆、卵磷脂、羟丙基-β-环糊精等;pH调剂剂可以是磷酸盐、酷酸盐、盐酸、氢氧化钠等;渗透压调节剂可以是氯化钠、甘露醇、葡萄糖、磷酸盐、醋酸盐等。如制备冻干粉针剂,还可加入甘露醇、葡萄糖等作为支撑剂。
此外,如需要,也可以向药物制剂中添加着色剂、防腐剂、香料、矫味剂或其它添加剂。为达到用药目的,增强治疗效果,本发明的药物或药物组合物可用任何公知的给药方法给药。本发明化合物药物组合物的给药剂量依照所要预防或治疗疾病的性质和严重程度,患者或动物的个体情况,给药途径和剂型等可以有大范围的变化。一般来讲,本发明化合物的每天的合适剂量范围为0.001-400mg/kg体重。上述剂量可以一个剂量单位或分成几个剂量单位给药,这取决于医生的临床经验以及包括运用其它治疗手段的给药方案。
本发明的化合物或组合物可单独服用,或与其他治疗药物或对症药物合并使用。当本发明的化合物与其它治疗药物存在协同作用时,应根据实际情况调整它的剂量。
本发明的有益效果在于:本发明采用高尿酸血症小鼠模型,对尿囊素抗高尿酸血症和/或抗痛风药物,尤其是降低血尿酸水平作用进行了考察,结果显示,通过口服给药尿囊素可显著降低小鼠血清尿酸水平,可显著增加OAT1、OCTN1的mRNA表达水平,所以为高尿酸血症和/或痛风的治疗预防与治疗提供了一种安全、有效、经济的解决办法。
附图说明
图1.尿囊素对高尿酸血症模型小鼠血清尿酸(UA)水平影响。n=10。
图2.尿囊素对高尿酸血症模型小鼠有机阴离子转运体1(OAT1)的mRNA表达水平影响。n=3。
图3.尿囊素对高尿酸血症模型小鼠有机阳离子转运体1(OCTN1)的mRNA表达水平影响。n=3。
具体实施方式
为使本发明的目的、技术方案、优点更加清楚,下面将结合附图对本发明作进一步的详细描述。
实验例1.尿囊素降低高尿酸血症模型小鼠血清尿酸(UA)水平。
实验材料:昆明小鼠购自北京市华阜康生物科技股份有限公司。氧嗪酸钾,尿囊素,别嘌呤醇,苯溴马隆购自西格玛奥德里奇(Sigma-Aldrich,Germany)。羧甲基纤维素钠购自国药集团化学试剂有限公司。尿酸试剂盒购自中生北控生物科技股份有限公司。
溶液配制:将1%羧甲基纤维素钠溶解,煮沸,冷却后作为溶媒,将尿囊素、氧嗪酸钾、别嘌呤醇、苯溴马隆分别溶解配置成混悬液。
实验分组:18-20g小鼠随机分为正常对照组,模型组,苯溴马隆组(25mg·kg-1,阳性对照),尿囊素低、高剂量组(100,400mg·kg-1),每组10只。
除对照组外每日腹腔注射氧嗪酸钾300mg·kg-1,正常对照组每日注射等量1%羧甲基纤维素钠溶液,连续造模8天,随后按分组给药,给药14天后处死小鼠,眼后静脉丛取血,静置2h,5000rpm,4℃离心10min取血清,用尿酸试剂盒测定血清尿酸水平。
结果:模型动物口服尿囊素(100,400mg/kg)后,血清尿酸水平均能一定程度的降低,提示口服尿囊素可以发挥抗高尿酸血症和/或抗痛风作用。
表1.尿囊素对高尿酸血症模型小鼠血清尿酸水平影响(n=10)。
与对照组比较,a:P<0.01,与模型组相比,b:P<0.05,c:P<0.01。
实验例2.尿囊素对高尿酸血症模型小鼠有机阴离子转运体1(OAT1)的mRNA表达水平影响。n=3。
实验分组:18-20g小鼠随机分为正常对照组,模型组,苯溴马隆组(25mg·kg-1,阳性对照),尿囊素低、高剂量组(100,400mg·kg-1),每组10只。相关溶液准备与实验方案同实施例1。逆转录试剂盒、SYBR green染料购自宝日医生物技术有限公司(TAKARA,Japan)。引物购自生工生物工程股份有限公司,纯化方式为HAP。
表2.OAT1引物及内参引物序列。
小鼠处死后,取小鼠肾脏,使用Trizol法提取肾脏中总RNA,用紫外分光光度计进行RNA定量,再用逆转录试剂盒进行逆转录得到对应cDNA,利用SYBRGreen染料进行实时荧光定量PCR,观察mRNA表达变化情况。
结果:模型动物口服尿囊素(400mg/kg)能够显著增加OAT1的表达,如表3所示,尿囊素可能通过增加离子转运体的表达,起到增加尿酸转运***而降低血浆尿酸浓度的效果。
表3.尿囊素对高尿酸血症模型小鼠OAT1的mRNA表达水平影响。n=3。
与对照组相比,a:P<0.05,与模型组相比,b:P<0.05,c:P<0.01。
实验例3.尿囊素对高尿酸血症模型小鼠有机阳离子转运体1(OCTN1)的mRNA表达水平影响。(n=3)。
实验分组:18-20g小鼠随机分为正常对照组,模型组,苯溴马隆组(25mg·kg-1,阳性对照),尿囊素低、高剂量组(100,400mg·kg-1),每组10只。相关溶液配制与实验方案同实施例2。逆转录试剂盒、SYBR green染料购自宝日医生物技术有限公司(TAKARA,Japan)。引物购自生工生物工程股份有限公司,纯化方式为HAP。
表4.OCTN1引物与内参引物序列。
小鼠处死后,取小鼠肾脏,使用Trizol法提取肾脏中总RNA,用紫外分光光度计进行RNA定量,再用逆转录试剂盒进行逆转录得到对应cDNA,利用SYBRGreen染料进行实时荧光定量PCR,观察mRNA表达变化情况。
结果:模型动物口服尿囊素(100mg/kg)能显著增加OCTN1的表达,如表5所示,尿囊素可能通过增加离子转运体的表达,起到增加尿酸转运体***而降低血浆尿酸浓度的效果。
表5.尿囊素对高尿酸血症模型小鼠OCTN1的mRNA表达水平影响。(n=3)。
与对照组相比,a:P<0.05,与模型组相比,b:P<0.05,c:P<0.01。
综上所述,本发明采用高尿酸血症小鼠模型对尿囊素抗高尿酸血症和/或抗痛风药物和/或保健品,尤其是降低血尿酸水平作用进行了考察,结果显示,通过灌胃给药尿囊素可显著降低小鼠血清尿酸水平,可显著增加OAT1、OCTN1的mRNA表达水平。因此,尿囊素有抗高尿酸血症和/或抗痛风作用。以尿囊素为活性物质,单独使用或/与其他具有药理学活性的化合物和/或提取物组成复方使用,按照药学领域的常规制剂方法制成各种剂型的抗高尿酸血症和/或抗痛风药物和/或保健品,或与其他促尿酸***药物和/或黄嘌呤氧化酶抑制剂等制成复方制剂,用于在保持疗效的情况下减少药物作用中的不良反应,可为高尿酸血症和/或痛风的治疗预防与治疗提供了一种安全、有效、经济的解决办法。
最后说明的是,以上实施例仅用于说明本发明的技术方案而非限制,尽管通过参照本非发明的优选实施例已对本发明进行了描述,但本领域普通技术人员应当理解,可以在实行上和细节上对其做出各种各样的改变,而不偏离所附权利要求说明书所限定的本发明的精神和范围。
Claims (7)
1.如式Ⅰ所示的N-(2,5-二氧代-4-咪唑啉啶基)尿素及其药学上可接受的盐在制备抗高尿酸血症和/或抗痛风产品中的应用
2.根据权利要求1的应用,所述高尿酸血症为原发性与继发性以及各种因素引起的通过磷钨酸还原法测定男性血液中尿酸浓度高于420μmol/L,女性血液中尿酸浓度高于357μmol/L,或通过尿酸酶-过氧化物酶偶联法测定成人血液中尿酸浓度高于420μmol/L。
3.根据权利要求1的应用,所述痛风为原发性痛风与继发性痛风。
4.一种药物组合物在制备抗高尿酸血症和/或抗痛风产品中的应用,其特征在于,含有权利要求1的N-(2,5-二氧代-4-咪唑啉啶基)尿素及其药学上可接受的盐、及药学上可接受的载体。
5.根据权利要求1的应用,其特征在于,所述的产品选自药物或保健品。
6.根据权利要求4的应用,其特征在于,所述的药物组合物选自口服制剂,注射给药剂型,皮肤黏膜途径给药剂型。
7.根据权利要求6的应用,其特征在口服制剂选自片剂、缓释剂、胶囊剂、控释剂、滴丸剂、液体制剂,所述的注射给药剂型选自肌肉注射、静脉注射、静脉滴注。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710467560.1A CN109091478A (zh) | 2017-06-20 | 2017-06-20 | 尿囊素在制备抗高尿酸血症和抗痛风药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710467560.1A CN109091478A (zh) | 2017-06-20 | 2017-06-20 | 尿囊素在制备抗高尿酸血症和抗痛风药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109091478A true CN109091478A (zh) | 2018-12-28 |
Family
ID=64795658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710467560.1A Pending CN109091478A (zh) | 2017-06-20 | 2017-06-20 | 尿囊素在制备抗高尿酸血症和抗痛风药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109091478A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113509464A (zh) * | 2021-07-16 | 2021-10-19 | 华侨大学 | 一种肠腔内尿酸吸附剂及其应用和制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015102642A1 (en) * | 2014-01-03 | 2015-07-09 | Scioderm, Inc. | Allantoin compositions for treating inflammatory skin conditions |
WO2016105448A1 (en) * | 2014-12-22 | 2016-06-30 | Darryl Rideout | Imidazoline receptor type 1 ligands for use as therapeutics |
-
2017
- 2017-06-20 CN CN201710467560.1A patent/CN109091478A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015102642A1 (en) * | 2014-01-03 | 2015-07-09 | Scioderm, Inc. | Allantoin compositions for treating inflammatory skin conditions |
WO2016105448A1 (en) * | 2014-12-22 | 2016-06-30 | Darryl Rideout | Imidazoline receptor type 1 ligands for use as therapeutics |
Non-Patent Citations (1)
Title |
---|
D. MASSEOUD 等: "Overview of Hyperuricaemia and Gout", 《CURRENT PHARMACEUTICAL DESIGN》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113509464A (zh) * | 2021-07-16 | 2021-10-19 | 华侨大学 | 一种肠腔内尿酸吸附剂及其应用和制备方法 |
CN113509464B (zh) * | 2021-07-16 | 2023-10-20 | 华侨大学 | 一种肠腔内尿酸吸附剂及其应用和制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2589382A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
CN103833713B (zh) | 硝克柳胺化合物晶iii型、其制法和其药物组合物与用途 | |
CN107530304A (zh) | Olig2活性的抑制 | |
CN109223707A (zh) | 一种尿酸酶外用凝胶制剂、其制备方法及用途 | |
CN109985033A (zh) | 丹酚酸c在制备抗脑卒中药物中的应用 | |
CN105902506A (zh) | 一种沙卡布曲缬沙坦制剂及其应用 | |
CN109091478A (zh) | 尿囊素在制备抗高尿酸血症和抗痛风药物中的应用 | |
CN109718230A (zh) | 丹酚酸a在制备抗高尿酸血症和抗痛风药物中的应用 | |
JPH05186360A (ja) | アレルギー性疾患用の治療剤及びエゾウコギ抽出物の製造方法 | |
CN104940181B (zh) | β‑羟丁酸或其药学上可接受的盐的用途 | |
CN115531393A (zh) | 麦角甾醇在制备防治胃溃疡药物中的应用 | |
CN103054932B (zh) | 楹树提取物在制备治疗胃溃疡药物中的应用 | |
CN113181167B (zh) | 草质素在制备治疗心肌肥厚药物中的应用 | |
CN102342949B (zh) | 根皮苷在制备治疗高尿酸血症药物中的应用 | |
WO2013111729A1 (ja) | 医薬組成物及びこれを用いた薬用化粧品 | |
AU2018101586A4 (en) | Uses of polydatin | |
CN112999213A (zh) | 蓓萨罗丁在制备抗垂体促肾上腺皮质激素腺瘤药物中的应用 | |
CN115920059B (zh) | 一种fxr受体抑制组合物、制备方法及其防治冠状病毒的应用 | |
CN102716128A (zh) | 一种治疗哮喘的药用组合物 | |
KR20200026156A (ko) | 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물 | |
CN105748427B (zh) | 一种托匹司他肠溶片及其制备方法 | |
CN105934245B (zh) | 多发性硬化症的治疗剂或预防剂 | |
CN100998587A (zh) | 5-羟基糠醛在制备药物中的应用 | |
CN102652749B (zh) | 2-环基氧或硫取代的羟基苯乙酮治疗新陈代谢疾病的应用 | |
CN109223815A (zh) | 一种药物组合物在制备治疗乙酰胆碱性荨麻疹药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181228 |